Skip to main content
Erschienen in: Rheumatology International 11/2018

09.08.2018 | Public Health

Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis

verfasst von: Klaus Krüger, Ulrich von Hinüber, Florian Meier, Haijun Tian, Katharina Böhm, Steffen M. Jugl, Kathrin Borchert, Dominic Meise, Christine König, Sebastian Braun

Erschienen in: Rheumatology International | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

To compare healthcare resource utilization and costs between ankylosing spondylitis (AS) patients and a matched sample from the general population without AS covered by the German Statutory Health Insurance (SHI) system, a non-interventional retrospectively matched cohort analysis was conducted using anonymized SHI claims data. Data from January 1st, 2011 through December 31st, 2014 were analyzed. Individuals with a coded diagnosis of AS during the enrollment period comprising the full year of 2013 were directly matched (1:5) to individuals without AS diagnosis in the whole study period by age, gender, hospitalizations, and comorbidities. All-cause healthcare resource utilization and direct costs were analyzed for the year 2013. Statistical tests were applied to compare the differences between the two sampled populations. In 2013, 10,208 AS patients were identified and matched to a sample of 51,040 patients without AS from the general population. Healthcare resource utilization was significantly higher in all healthcare sectors (inpatient, outpatient, pharmaceuticals, remedies, devices and aids, and sick leave) in the AS cohort. Mean all-cause healthcare costs per patient were about €2475 higher in the AS cohort compared to the general population. Most important cost drivers were hospitalizations and pharmaceuticals in terms of bDMARDs prescribed in 10% of the patients. Real-world data from this German claims database analysis showed that AS is associated with a substantial incremental economic burden to the healthcare system.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Boonen A, van der Linden SM (2006) The burden of ankylosing spondylitis. J Rheumatol Suppl 78:4–11PubMed Boonen A, van der Linden SM (2006) The burden of ankylosing spondylitis. J Rheumatol Suppl 78:4–11PubMed
2.
Zurück zum Zitat Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20(6; SUPP/28):S–S16 Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20(6; SUPP/28):S–S16
3.
Zurück zum Zitat Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27:613–622PubMed Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27:613–622PubMed
5.
Zurück zum Zitat Kiltz U, Braun J (2013) Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen Kiltz U, Braun J (2013) Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen
6.
Zurück zum Zitat Shaikh SA (2007) Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc 51:249–260PubMedPubMedCentral Shaikh SA (2007) Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc 51:249–260PubMedPubMedCentral
7.
Zurück zum Zitat Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67CrossRef Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67CrossRef
8.
Zurück zum Zitat Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d’Elia H, Neovius M, Turesson C, Kristensen LE, Jacobsson LT (2015) The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther 17(1):1–9CrossRef Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d’Elia H, Neovius M, Turesson C, Kristensen LE, Jacobsson LT (2015) The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther 17(1):1–9CrossRef
9.
Zurück zum Zitat Haroon NN, Paterson JM, Li P, Haroon N (2014) Increasing proportion of female patients with ankylosing spondylitis: a population-based study of trends in the incidence and prevalence of AS. BMJ Open 4(12):e006634CrossRef Haroon NN, Paterson JM, Li P, Haroon N (2014) Increasing proportion of female patients with ankylosing spondylitis: a population-based study of trends in the incidence and prevalence of AS. BMJ Open 4(12):e006634CrossRef
10.
Zurück zum Zitat Boonen A, Chorus A, Miedema H, van Der Heijde D, van Der Tempel H, Van der Linden S (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60(4):353–358CrossRef Boonen A, Chorus A, Miedema H, van Der Heijde D, van Der Tempel H, Van der Linden S (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60(4):353–358CrossRef
11.
Zurück zum Zitat Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61:iii8–iii18CrossRef Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61:iii8–iii18CrossRef
12.
Zurück zum Zitat Boonen A (2002) Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 16(4):691–705CrossRef Boonen A (2002) Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 16(4):691–705CrossRef
13.
Zurück zum Zitat Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden SJ, Brandt J (2002) Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61:iii40–iii50CrossRef Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden SJ, Brandt J (2002) Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61:iii40–iii50CrossRef
14.
Zurück zum Zitat van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2016-210770 CrossRefPubMedPubMedCentral van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. https://​doi.​org/​10.​1136/​annrheumdis-2016-210770 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS (2015) Secukinumab, an Interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548. https://doi.org/10.1056/NEJMoa1505066 CrossRef Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS (2015) Secukinumab, an Interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548. https://​doi.​org/​10.​1056/​NEJMoa1505066 CrossRef
16.
Zurück zum Zitat National Institute for Health and Care Excellence (2016) TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383). Technology appraisal guidance. National Institute for Health and Care Excellence, London National Institute for Health and Care Excellence (2016) TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383). Technology appraisal guidance. National Institute for Health and Care Excellence, London
17.
Zurück zum Zitat Franke L, Ament A, Laar M, Boonen A, Severens J (2009) Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4, Suppl. 55):118–123 Franke L, Ament A, Laar M, Boonen A, Severens J (2009) Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4, Suppl. 55):118–123
19.
Zurück zum Zitat Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, Turchetti G (2012) A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 30(4 Suppl 73):S136–S141PubMed Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, Turchetti G (2012) A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 30(4 Suppl 73):S136–S141PubMed
21.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRef
22.
Zurück zum Zitat Statistisches Bundesamt (2017) DESTATIS Bevölkerung und Erwerbstätigkeit, Bevölkerung mit Migrationshindergrund, Ergebnisse des Mikrozensus 2013 Statistisches Bundesamt (2017) DESTATIS Bevölkerung und Erwerbstätigkeit, Bevölkerung mit Migrationshindergrund, Ergebnisse des Mikrozensus 2013
23.
Zurück zum Zitat Huscher D, Thiele K, Rudwaleit M, Albrecht KC, Bischoff S, Krause A, Karberg K, Wassenberg S, Zink A (2015) Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. RMD Open 1(1):e000033CrossRef Huscher D, Thiele K, Rudwaleit M, Albrecht KC, Bischoff S, Krause A, Karberg K, Wassenberg S, Zink A (2015) Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. RMD Open 1(1):e000033CrossRef
24.
Zurück zum Zitat Gran J, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 44:359–367CrossRef Gran J, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 44:359–367CrossRef
25.
Zurück zum Zitat van der Linden SM, Valkenburg HA, de Jongh BM, Cats A (1984) The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 27(3):241–249 van der Linden SM, Valkenburg HA, de Jongh BM, Cats A (1984) The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 27(3):241–249
26.
Zurück zum Zitat Feldtkeller E (1999) Age at disease onset and delayed diagnosis of spondyloarthropathies. Z Rheumatol 58(1):21–30CrossRef Feldtkeller E (1999) Age at disease onset and delayed diagnosis of spondyloarthropathies. Z Rheumatol 58(1):21–30CrossRef
27.
Zurück zum Zitat Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462CrossRef Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462CrossRef
28.
Zurück zum Zitat Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A (2013) Health care costs associated with ankylosing spondylitis in Turkey: an analysis from nationwide real-world data. Int J Rheumatol 2013:139608CrossRef Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A (2013) Health care costs associated with ankylosing spondylitis in Turkey: an analysis from nationwide real-world data. Int J Rheumatol 2013:139608CrossRef
30.
Zurück zum Zitat Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG (2011) Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 13(Suppl 1):S4PubMedPubMedCentral Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG (2011) Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 13(Suppl 1):S4PubMedPubMedCentral
31.
Zurück zum Zitat Deutschen Gesellschaft für Rheumatologie (2013) Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen—Langfassung zur S3—Leitlinie. AWMF-Leitlinien Register Nummer: 060/003, Entwicklungsstufe: S3 Version: November 2013 Deutschen Gesellschaft für Rheumatologie (2013) Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen—Langfassung zur S3—Leitlinie. AWMF-Leitlinien Register Nummer: 060/003, Entwicklungsstufe: S3 Version: November 2013
32.
Zurück zum Zitat Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65(9):1175–1183CrossRef Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65(9):1175–1183CrossRef
33.
Zurück zum Zitat Wang BC, Tan CH, Furnback W, Ney JP, Yang YW, Fang CH, Chen WS (2015) Disease burden of ankylosing spondylitis in Taiwan: a population-based analysis. Ann Rheum Dis 74(512):FRI0242 Wang BC, Tan CH, Furnback W, Ney JP, Yang YW, Fang CH, Chen WS (2015) Disease burden of ankylosing spondylitis in Taiwan: a population-based analysis. Ann Rheum Dis 74(512):FRI0242
34.
Metadaten
Titel
Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis
verfasst von
Klaus Krüger
Ulrich von Hinüber
Florian Meier
Haijun Tian
Katharina Böhm
Steffen M. Jugl
Kathrin Borchert
Dominic Meise
Christine König
Sebastian Braun
Publikationsdatum
09.08.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 11/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4124-z

Weitere Artikel der Ausgabe 11/2018

Rheumatology International 11/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.